ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ZNTL vs ALXO // DIVIDEND YIELD & FCF PAYOUT SAFETY

Zentalis Pharmaceuticals Inc. (NASDAQ) VS. ALX Oncology Holdings Inc. (NASDAQ) • 15-METRIC TALLY: ZNTL 1 — ALXO 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZNTL VS. ALXO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ZNTL ALXO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 ALXO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 28.5 56.4 -27.90 ALXO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $175.1M $171.1M $4.0M ZNTL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ZNTL REV ALXO REV ZNTL GROSS % ALXO GROSS % ZNTL FCF ALXO FCF
FY 2025 $427.9M $291.3M — — -$125.2M -$84.4M
FY 2024 $67.4M $398.9M — — -$171.1M -$122.4M
FY 2023 $838.6M $476.8M — — -$207.8M -$130.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZNTL // BETA —
ALXO // BETA —